AI Article Synopsis
- Psoriasis severity classifications guide treatment decisions but can lead to miscategorization and undertreatment due to varying definitions and neglecting factors like special area involvement and treatment history.
- A consensus statement proposed by the International Psoriasis Council suggests two categories for psoriasis severity: candidates for topical therapy and candidates for systemic therapy, determined by specific criteria such as body surface area.
- While the consensus aims to improve classification, it may lack diverse stakeholder input, particularly from patients, which could impact its overall effectiveness and acceptance.
Article Abstract
Background: Psoriasis severity categories have been important tools for clinicians to use in treatment decisions as well as to determine eligibility criteria for clinical studies. However, owing to the heterogeneity of severity classifications and their lack of consideration for the impact of psoriasis involvement of special areas or past treatment history, patients may be miscategorized, which can lead to undertreatment of psoriasis.
Objective: To develop a consensus statement on the classification of psoriasis severity.
Methods: A modified Delphi approach was developed by the International Psoriasis Council to define psoriasis severity.
Results: After completion of the exercise, 7 severity definitions were preferentially ranked. This most preferred statement rejects the mild, moderate, and severe categories in favor of a dichotomous definition: Psoriasis patients should be classified as either candidates for topical therapy or candidates for systemic therapy; the latter are patients who meet at least one of the following criteria: (1) body surface area >10%, (2) disease involving special areas, and (3) failure of topical therapy.
Limitations: This effort might have suffered from a lack of representation by all relevant stakeholders, including patients.
Conclusion: The consensus statement describes 2 categories of psoriasis severity, while accounting for special circumstances where patients may require systemic therapy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jaad.2019.08.026 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Higher serotonin levels among patients with rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis compared to healthy controls assessed by liquid chromatography-tandem mass spectrometry (LC-MS).
Rheumatol Int
January 2025
Department of Rheumatology and Immunology, Jagiellonian University Medical College, Jakubowskiego 2, Kraków, 30-688, Poland.
Growing evidence suggests that serotonin is an important mediator in the cross-talk between immune and bone cells, playing a role in the pathogenesis of various types of inflammatory arthritis (IA). However, the relationship between circulating serotonin and different outcomes in three most prevalent IA - rheumatoid arthritis (RA), psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA), remains limited and requires further investigation. This study was performed to evaluate variations in serotonin serum levels among RA, PsA, and axSpA and to explore the utility of this biochemical marker in the assessment of disease activity and health status measurements provided by the Multi-Dimensional Health Assessment Questionnaire (MDHAQ).
View Article and Find Full Text PDFPatterns of Addiction in Chronic Skin Diseases: A Comparative Analysis of Addictions and Influencing Factors in Atopic Dermatitis and Psoriasis.
Acta Derm Venereol
January 2025
Department of Dermatology and Allergy, TUM School of Medicine and Health, Technical University of Munich, Munich, Germany.
Addictions seem to be more frequent in atopic dermatitis and psoriasis patients than in the general population. This cross-sectional observational study comparatively evaluated substance-related and behavioural addictions in atopic dermatitis and psoriasis patients and analysed possible addiction patterns. From October 2023 to April 2024, 100 atopic dermatitis and 104 psoriasis patients at a German university hospital completed an anonymous questionnaire, including sociodemographic and health-related parameters, along with validated assessment tools for common addictions (smoking, gambling, alcohol, drugs, food, and internet).
View Article and Find Full Text PDFManagement of psoriasis in women 18 to 45 years of age in Australia and Japan: insights from patient and dermatologist surveys.
Int J Womens Dermatol
March 2025
St Vincent's Hospital, Westmead Hospital, University of Sydney, New South Wales, Australia.
Background: A psoriasis (PSO) diagnosis may pose specific treatment challenges for women of childbearing age (WoCBA) who are considering pregnancy, are pregnant, or have just given birth.
Objective: To report perspectives of WoCBA with PSO regarding pregnancy and dermatologists about the disease management of these women in Australia and Japan.
Methods: Online surveys were completed by women aged 18 to 45 years who were pregnant within the past 5 years with moderate to severe PSO and dermatologists.
Treatment satisfaction among patients with psoriasis in Saudi Arabia.
Dermatol Reports
November 2024
Department of Medicine and Surgery, King Faisal University, Al-Ahsa, Saudi Arabia.
Psoriasis, affecting 2% of the population, burdens individuals physically and emotionally, with adherence challenges (39-73%). Treatment ranges from topical to systemic therapy, including bio-logics. Although biologic therapy improves clinical outcomes, side effects lead 50% of severe cases to prefer topical treatment.
View Article and Find Full Text PDFClinical implications of human Parvovirus B19 infection on autoimmunity and autoimmune diseases.
Int Immunopharmacol
January 2025
Institute of Medicine, Chung Shan Medical University, Taichung 402, Taiwan; Department of Clinical Laboratory, Chung Shan Medical University Hospital, Taichung 402, Taiwan; Immunology Research Center, Chung Shan Medical University, Taichung 402, Taiwan. Electronic address:
Parvovirus B19 (B19V) is a human pathogen from the Parvoviridae family that primarily targets and replicates in erythroid progenitor cells (EPCs). While its symptoms are typically self-limiting in healthy individuals, B19V can cause or exacerbate autoimmune diseases in vulnerable patients. This review integrates the involvement of B19V in the development and worsening of several autoimmune diseases, including systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), hematological disorders (thalassemia, anemia, and thrombocytopenia), vasculitis, antiphospholipid syndrome (APS), dermatological disease (systemic sclerosis, psoriasis), autoimmune thyroid disease, myocarditis, and myasthenia gravis, and autoinflammatory disease of adult-onset Still's disease (AOSD).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!